Sign In
Buy ERAS
$18.15
-0.530 (-2.84%)
At Close: Jul 31, 2026
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
03:40pm, Monday, 18'th May 2026
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
01:58pm, Sunday, 17'th May 2026
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference
03:06pm, Saturday, 16'th May 2026
Erasca NASDAQ: ERAS executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and co
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
10:41am, Saturday, 16'th May 2026
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
12:00am, Friday, 15'th May 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
11:01pm, Thursday, 14'th May 2026
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Da
ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
08:00pm, Thursday, 14'th May 2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) inve
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Erasca (ERAS) To Contact Him Directly To Discuss Their Options
Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
08:50pm, Wednesday, 13'th May 2026
Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
08:00pm, Tuesday, 12'th May 2026
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whet
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
04:56pm, Tuesday, 12'th May 2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised
Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks
06:25pm, Monday, 11'th May 2026
I initiate Erasca (ERAS) with a "Hold" rating due to promising phase 1 ERAS-0015 data but significant risks. ERAS-0015 showed high ORR in KRAS-mutant NSCLC [64%] and PDAC [50%] at RDE but faces safety
Erasca Reports First Quarter 2026 Business Updates and Financial Results
04:01pm, Monday, 11'th May 2026
Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targ
ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in
ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm
07:29pm, Sunday, 10'th May 2026
LOS ANGELES, May 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Erasca, Inc. ("Era
